ESMO TAT 2021 | Efficacy and safety of MEDI1191 in patients with solid tumors and superficial lesions
Omid Hamid
• 12 Mar 2021
Omid Hamid, MD, Cedars-Sinai Medical Center, Los Angeles, CA, presents findings from the Phase I trial (NCT03946800), which evaluated safety and efficacy of MEDI1191 (IL-12 mRNA) in combination with durvalumab in patients with solid tumors. Intratumoral injection of MEDI1191 resulted in localized production of IL-12 in the tumor, stimulating immune cell and IFN gamma production, as well as inducing cytotoxic T cell activity into the tumor area. In the ongoing trial with 10 patients, one patient with head and neck cancer and another with melanoma had a partial clinical response, demonstrating proof of principle. This interview took place during the ESMO TAT 2021 conference.
